Jim Cramer Discusses Key Point For Eli Lilly (LLY)'s Drugs

We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed.

Eli Lilly and Company (NYSE:LLY) is the pharmaceutical giant best known for its weight loss drugs. Cramer regularly discusses the firm in his morning appearances and on Mad Money. The CNBC TV host believes that Eli Lilly and Company (NYSE:LLY) can benefit from a pill form for its weight loss drug. In this appearance, he discussed the potential for comorbidities to further help the stock and ratings action by BMO Capital:

“Lilly has another version of a, of a drug that’s in phase two. That sounds very promising. Very, 20%, 20 pounds I’m sorry, the weight loss. There are rumors that it’s more fat than muscle, that’s lost.

“I think it anticipating this, and also the fact that it’s perhaps that possible with  comorbidities that everybody can get this and get reimbursed. It’s the comorbidity issue that’s so important.

“[On BMO going to 1100] Yeah, Lilly, I remember speaking to Ken Langone and he said, listen, Lilly is going to be the first non-tech company to go to a trillion dollars. I’m including that in my book, How to Make Money in Any Market, which people are starting to use the initials, which is ridiculous cause I don’t even know that.  But it’s 880 billion, getting there. Getting there.”

While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.